Abstract

Since the beginning of this new century, drug development is changing; the concern of protecting children against clinical research is fading away and a new paradigm, which is not yet necessarily accepted by all of society, is now emerging; that of protecting children through clinical research. It is unethical to withold available treatments from children because of lack of research, consequently it is expected that the number of pediatric clinical trials will increase in the future. However, research is not deprived of risks, and it is necessary to maintain a perfectly well-balanced, scientific and ethical approach when designing pediatric clinical trials. Child psychopharmacology provides an opportunistic paradigm of the difficulties and challenges of pediatric drug development. The hurdles of developing and conducting research in the pediatric population are numerous and some of them are more exacerbated in the field of child and adolescent psychiatry than in other pediatric areas such as pediatric onc...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.